Guidelines for the treatment of arterial hypertension;Leitlinien zur behandlung der arteriellen hypertonie

Nieren- und Hochdruckkrankheiten

Volumn 38, Issue 4, 2009, Pages 137-188

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANDESARTAN; CHLORTALIDONE; DIHYDRALAZINE; DIHYDROPYRIDINE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; EPROSARTAN; INDAPAMIDE; ISRADIPINE; LACIDIPINE; LISINOPRIL; LOSARTAN; METHYLDOPA; METOPROLOL; NIFEDIPINE; NITRENDIPINE; PERINDOPRIL; PLACEBO; RAMIPRIL; TELMISARTAN; THIAZIDE DIURETIC AGENT; UNINDEXED DRUG; VALSARTAN; VERAPAMIL;

ARTERIOSCLEROSIS; CARDIOVASCULAR RISK; COGNITIVE DEFECT; DEMENTIA; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; EMBRYOTOXICITY; FETOTOXICITY; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; MALIGNANT HYPERTENSION; METABOLIC SYNDROME X; MONOTHERAPY; MORBIDITY; PRACTICE GUIDELINE; PROGNOSIS; REVIEW; SYSTOLIC BLOOD PRESSURE; UNSPECIFIED SIDE EFFECT;

EID: 66149164475     PISSN: 03005224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (290)

1. Mancia G, De Backer G, Dominiczak A, Cifkova R, et al. Guidelines for the management of arterial hypertension. J Hypertens. 2007; 25; 1105-1187.
2. Guidelines Committee. European Society of Hypertension-European Society of Cardiology guidelines for the managementof arterial hypertension. J Hypertens. 2003; 21: 1011-1053. GL
3. Collins R, Peto R, MacMahon S, Herbert P, Fieback NH, Eberlein KA et al. Blood pressure, stroke, and coronary heart disease. Part 2. Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet. 1990; 335: 827-839. MA
4. MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J et al. Blood pressure, stroke, and coronary heart disease. Part 1. Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet. 1990; 335: 765-774. MA
5. Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002; 360: 1903-1913. MA
6. Kjeldsen SE, Julius S, Hedner T, Hansson L. Stroke is morecommonthan myocardial infarction in hypertension: analysis based on 11 major randomized intervention trials. Blood Press. 2001; 10: 190-192. RV (Pubitemid 33149897)
7. Primatesta P, Brookes M, Poulter NR. Improved hypertension management and control. Results from the Health Survey for England 1998. Hypertension. 2001; 38: 827-832.
8. O'Rourke MF. From theory into practice. Arterial hemodynamics in clinical hypertension. J Hypertens. 2002; 20: 1901-1915. OS
9. Millar JA, Lever AF, Burke A. Pulse pressure as a risk factor for cardiovascular events in the MRC Mild Hypertension Trial. J Hypertens. 1999; 17: 1065-1072. OS
10. Franklin S, Khan SA, Wong DA, Larson MG, Levy D. Is pulse pressure useful in predicting risk for coronary heart disease? The Framingham Heart Study. Circulation. 1999; 100: 354-360. OS (Pubitemid 29362404)
11. Franklin S, Larson MG, Khan SA, Wong ND, Leip EP, Kannel WB, Levy D. Does the relation of blood pressure to coronary heart disease risk change with aging? The Framingham Heart Study. Circulation. 2001; 103: 1245-1249. OS (Pubitemid 32221347)
12. Benetos A, Zureik M, Morcet J, Thomas F, Bean K, Safar M et al. A decrease in diastolic blood pressure combined with an increase in systolic blood pressure is associated with a higher cardiovascular mortality in men. J Am Coll Cardiol. 2000; 35: 673-680. OS (Pubitemid 30167024)
13. SHEP Collaborative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 1991; 265: 3255-3264. RT
14. Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhäger WH et al. for the Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Randomised double-blind comparison of plazebo and active treatment for older patients with isolated systolic hypertension. Lancet. 1997; 350: 757-764. RT
15. O'Rourke MF. Principles and definitions of arterial stiffness, wave reflections and pulse pressure amplification. In: Safar ME, O'Rourke MF (eds). Arterial stiffness in hypertension. Handbook of Hypertension, Elsevier; 2006, Vol 23, pp. 3-19. RV
16. Morgan T, Lauri J, Bertram D, Anderson A. Effect of different antihypertensive drug classes on central aortic pressure. Am J Hypertens. 2004; 17: 118-123. (Pubitemid 38125127)
17. Chen CH, Nevo E, Felics B, Pak PH, Yin PC, Maughan WL, Kass DA. Estimation of central aortic pressure waveform by mathematic transformation of radial tonometry pressure. Validation of generalized transfer function. Circulation. 1997; 95: 1827-1836.
18. Evans JG, Rose G. Hypertension. Br Med Bull. 1971; 27: 37-42. RV
19. Meigs JB, D'Agostino RB Sr, Wilson PW, Cupples LA, Nathan DM, Singer DE. Risk variable clustering in the insulin resistance syndrome. The Framingham Offspring Study. Diabetes. 1997; 46: 1594-1600. OS
20. Stamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356.222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA. 1986; 256: 2823-2828. OS (Pubitemid 17178359)
21. Jackson R. Updated New Zealand cardiovascular disease risk-benefit prediction guide. Br Med J. 2000; 320: 709-710. OS (Pubitemid 30179401)
22. Anderson KM, Wilson PW, Odell PM, Kannel WB. An updated coronary risk profile. A statement for health professionals. Circulation. 1991; 83: 356-362. OS
23. Haq IU, Ramsay LE, Yeo WW, Jackson PR, Wallis EJ. Is the Framingham risk function valid for northern European populations? A comparison of methods for estimating absolute coronary risk in high risk men. Heart. 1999; 81: 40-46. OS
24. Menotti A, Puddu PE, Lanti M. Comparison of the Framingham risk function-based coronary chart with risk function from an Italian population study. Eur Heart J. 2000; 21: 365-370. OS (Pubitemid 30107553)
25. Keil U, Liese AD, Hense HW, Filipiak B, Doring A, Stieber J et al. Classical risk factors and their impact on incident nonfatal and fatal myocardial infarction and all-cause mortality in southern Germany. Results from the MONICA Augsburg cohort study 1984-1992. Monitoring Trends and Determinants in Cardiovascular Diseases. Eur Heart J. 1998; 19: 1197-1207. OS (Pubitemid 28362603)
26. Tunstall-Pedoe H, Woodward M, Tavendale R, Brook R, McCluskey MK. Comparison of the prediction by 27 different factors of coronary heart disease and death in men and women of the Scottish heart health study: cohort study. Br Med J. 1997; 315: 722-729. OS (Pubitemid 27405828)
27. Vartiainen E, Jousilahti P, Alfthan G, Sundvall J, Pietinen P, Puska P. Cardiovascular risk factor changes in Finland, 1972-1997. Int J Epidemiol. 2000; 29: 49-56. OS
28. Pocock SJ, McCormack V, Gueyffier F, Boutitie F, Fagard RH, Boissel JP. Ascore for predicting risk of death from cardiovascular disease in adults with raised blood pressure, based on individual patient data from randomised controlled trials. Br Med J. 2001; 323: 75-81. OS (Pubitemid 32681971)
29. Conroy RM, Pyörälä K, Fitzgerald AP, Sans S, Menotti A, De Backer G et al. on behalf of the SCORE project group. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003; 24: 987-1003. OS
30. Simpson FO. Guidelines for antihypertensive therapy: problems with a strategy based on absolute cardiovascular risk. J Hypertens. 1996; 14: 683-689. (Pubitemid 26187401)
31. Zanchetti A. Antihypertensive therapy. How to evaluate the benefits. Am J Cardiol. 1997; 79: 3-8.
32. Franklin SS, Wong ND. Cardiovascular risk evaluation: an inexact science. J Hypertens. 2002; 20: 2127-2130. (Pubitemid 35388224)
33. Reaven G. Metabolic syndrome: pathophysiology and implications for management of cardiovascular disease. Circulation. 2002; 106: 286-288.
34. Tuomilehto J, Rastenyte D, Birkenhäger WH,Thijs L, Antikanen R, Bulpitt CJ et al. Effects of calcium channel blockade in older patients with diabetes and systolic hypertension. N Engl J Med. 1999; 340: 677-684. RT (Pubitemid 29110751)
35. Ruilope LM, Salvetti A, Jamerson K, Hansson L, Warnold I, Wedel H, Zanchetti A. Renal function and intensive lowering of blood pressure in hypertensive participants of the Hypertension Optimal Treatment (HOT) study. J Am Soc Nephrol. 2001; 12: 218-225. RT (Pubitemid 32116363)
36. Cockroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976; 16: 31-41.
37. Hallan S, Asberg A, Lindberg M, Johnsen H. Validation of the Modification of Diet in Renal Disease formula for estimating GFR with special emphasis on calibration of the serum creatinine assay. Am J Kidney Dis. 2004; 44: 84-93. (Pubitemid 38880931)
38. Willum-Hansen T, Staessen JA, Torp-Pedersen C, Rasmussen S, Thijs L, Ibsen H, Jeppesen J. Prognostic value of aortic pulse wave velocity as index of arterial stiffness in the general population. Circulation. 2006; 113: 664-670. OS (Pubitemid 43754330)
39. Laurent S, Boutouyrie P, Asmar R, Gautier I, Laloux B, Guize L et al. Aortic stiffness as an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension. 2001; 37: 1236-1241. OS (Pubitemid 34163575)
40. Feringa HH, Bax JJ, van Waning VH, Boersma E, Elhendy A, Schouten O et al. The long-term prognostic value of the resting and postexercise ankle-brachial index. Arch Int Med. 2006; 166: 529-535. OS
41. Yikona JI, Wallis EJ, Ramsay LE, Jackson PR. Coronary and cardiovascular risk estimation in uncomplicated mild hypertension. A comparison of risk assessment methods. J Hypertens. 2002; 20: 2173-2182. OS
42. PROGRESS Collaborative Study Group. Randomised trial of perindopril based blood pressure- lowering regimen among 6.108 individuals with previous stroke or transient ischaemic attack. Lancet. 2001; 358: 1033-1041. RT
43. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000; 342: 145-153. RT
44. The EURopa trial on reduction of cardiac events with perindopril in stable coronary artery disease investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, doubleblind, plazebo-controlled multicentre trial (the EUROPAstudy). Lancet. 2003; 362: 782-788. RT
45. Nissen SE, Tuzou EM, Libby P, Thompson PD, Ghali M, Garza D et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA. 2004; 292: 2217-2225. RT (Pubitemid 39473159)
46. Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet. 1998; 351: 1755-1762. RT (Pubitemid 28269185)
47. Schrier RW, Estacio RO, Esler A, Mehler P. Effects of aggressive blood pressure control in normotensive Type 2 diabetic patients on albuminuria, retinopathy and stroke. Kidney Int. 2002; 61: 1086-1097. RT (Pubitemid 34175478)
48. Hypertension Detection and Follow-up Program. The effect of treatment on mortality in "mild" hypertension: results of the Hypertension Detection and Follow-up Program. N Engl J Med. 1982; 307: 976-980. RT
49. Zanchetti A, Hansson L, Ménard J, Leonetti G, Rahn K,Warnold I et al. Risk assessment and treatment benefit in intensively treated hypertensive patients of the Hypertension Optimal Treatment (HOT) study for the HOT Study Group. J Hypertens. 2001; 19: 819-825. OS (Pubitemid 32289563)
50. Mancia G, Grassi G. Systolic and diastolic blood pressure control in antihypertensive drug trials. J Hypertens. 2002; 20: 1461-1464. RV
51. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, Hua T, Laragh JH, McInnnes GT, Mitchell L, Plat F, Schork A, Smith B, Zanchetti A. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: theVALUE randomised trial. Lancet. 2004; 363: 2022-2031. RT (Pubitemid 38781102)
52. Pepine CJ, Kowey PR, Kupfer S, Kolloch RE, Benetos A, Mancia G et al. Predictors of adverse outcome among patients with hypertension and coronary artery disease. J Am Coll Cardiol. 2006; 47: 547-551 (Pubitemid 43170842)
53. Liu L, Zhang Y, Liu G, Zhang X, Zanchetti A. The Felodipine Event Reduction (FEVER) Study: a randomized, placebo-controlled trial in Chinese hypertensive patients. J Hypertens. 2005; 23: 2157-2172. RT (Pubitemid 41666745)
54. Zanchetti A, Ruilope LM. Antihypertensive treatment in patients with Type 2 diabetes mellitus: what guidance from recent controlled randomized trials? J Hypertens. 2002; 20: 2099-2110. RV
55. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in Type 2 diabetes. UKPDS38. Br Med J. 1998; 317: 703-713. RT
56. Zanchetti A, Hansson L, Clement D, Elmfeldt D, Julius S, Rosenthal T et al. on behalf of the HOT Study Group. Benefits and risks of more intensive blood pressure lowering in hypertensive patients of the HOTStudy with different risk profiles: does a J-shaped curve exist in smokers? J Hypertens. 2003; 21: 797-804. RT
57. Heart Outcomes Prevention Evaluation (HOPE) Study investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICROHOPE substudy. Lancet. 2000; 355: 253-259. RT
58. Patel A, MacMahon S, Chalmers J, Neal B, Woodward M, Billot I et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with Type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007; 370: 829-840. RT (Pubitemid 47362321)
59. Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin independent diabetes and hypertension. N Engl J Med. 1998; 338: 645-652. RT
60. Adler AL, Stratton IM, Neil HA, Yudkin JS, Matthews DR, Cull CA et al. Association of systolic blood pressure with macrovascular and microvascular complications of Type 2 diabetes (UKPDS 36): prospective observational study. Brit Med J. 2000; 321: 412-429. OS
61. Peterson JC, Adler S, Burkart JM, Greene T, Hebert LA, Hunsicker LG et al. Blood pressure control, proteinuria, and the progression of renal disease.The Modification of Diet in Renal Disease Study. Ann Intern Med. 1995; 123: 754-762. CT
62. Sarnak MJ, Greene T, Wang X,Beck G,Kusek JW,Collins AJ et al. The effect of a lower target blood pressure on the progression of kidney disease: long-term follow-up of the modification of diet in renal disease study. Ann Intern Med. 2005; 142: 342-351. CT (Pubitemid 40293407)
63. Arima H, Chalmers J, Woodward M, Anderson C, Rodgers A, Davis S et al. Lower target blood pressures are safe and effective for the prevention of recurrent stroke: the PROGRESS trial. J Hypertens. 2006; 24: 1201-1208. OS (Pubitemid 43772329)
64. The PEACE trial investigators. Angiotensin-converting enzyme inhibition in stable coronary artery disease. New Engl J Med. 2004; 351: 2058-2068. RT
65. Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, de Jong PE et al. Progression of chronic kidney disease: The role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition. A patient-level metaanalysis. Ann Intern Med. 2003; 139: 244-252. MA (Pubitemid 38129085)
66. Clement DL, De Buyzere ML, De Bacquer DA, De Leeuw PW, Duprez DA, Fagard RH et al. Prognostic value of ambulatory blood pressure recordings in patients with treated hypertension. N Engl J Med. 2003; 348: 2407-2415. OS
67. Doll R, Peto R, Wheatley K, Gray R, Sutherland I. Mortality in relation to smoking: 40-year observational study on male British doctors. Br Med J. 1994; 309: 901-911. OS (Pubitemid 2140439)
68. Primatesta P, Falaschetti E, Gupta S, Marmot MG, Poulter NR. Association between smoking and blood pressure: evidence from the health survey for England. Hypertension. 2001; 37: 187-193. OS (Pubitemid 32199072)
69. Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. Medical Research Council. Br Med J. 1985; 291: 97-104. RT
70. Silagy C, Mant D, Fowler G, Lodge M. Meta-analysis on efficacy of nicotine replacement therapies in smoking cessation. Lancet. 1994; 343: 139-142. MA (Pubitemid 24028640)
71. Tonstad S, Farsang C, Kläne, Lewis K, Manolis A, Perrouhoud AP et al. Buproprin SR for smoking cessation in smokers with cardiovascular disease: a multicentre, randomised study. Eur Heart J. 2003; 24: 947-956. RT (Pubitemid 36559988)
72. Puddey IB, Beilin LJ, Rakie V. Alcohol, hypertension and the cardiovascular system: a critical appraisal. Addict Biol. 1997; 2: 159-170. RV
73. Wannamethee SG, Shaper AG. Patterns of alcohol intake and risk of stroke in middle-aged British men. Stroke. 1996; 27: 1033-1039. OS
74. Puddey IB, Beilin LJ, Vandongen R. Regular alcohol use raises blood pressure in treated hypertensive subjects. A randomised controlled trial. Lancet. 1987; 1: 647-651. RT
75. Stamler J. Epidemiologic findings on body mass and blood pressure in adults. Ann Epidemiol. 1991; 1: 347-362. OS
76. Reid CM, Dart AM, Dewar EM, Jennings GL. Interactions between the effects of exercise and weight loss on risk factors, cardiovascular haemodynamics and left ventricular structure in overweight subjects. J Hypertens. 1994; 12: 291-301. OS
77. Whelton PK, Appel LJ, Espeland MA, Applegate WB, Ettinger WH Jr, Kostis JB et al. Sodium reduction and weight loss in the treatment of hypertension in older persons: a randomized controlled trial of nonpharmacologic interventions in the elderly (TONE). TONE Collaborative Research Group. JAMA. 1998; 279: 839-846. RT
78. Sandvik L, Erikssen J, Thaulow E, Erikssen G, Mundal R, Rodahl K. Physical fitness as a predictor of mortality among healthy, middle-aged Norwegian men. N Engl J Med. 1993; 328: 533-537. OS (Pubitemid 23053829)
79. Jennings GL. Exercise and blood pressure: Walk, run or swim? J Hypertens. 1997; 15: 567-569. RV
80. Fagard RH. Exercise characteristics and the blood pressure response to dynamic physical training. Med Sci Sports Exerc. 2001; 33 (Suppl.): S484-S492. RV
81. Puddey IB, Cox K. Exercise lowers blood pressure - sometimes? Or did Pheidippides have hypertension? J Hypertens. 1995; 13: 1229-1233. RV
82. Law MR. Epidemiological evidence on salt and blood pressure. Am J Hypertens. 1997; 10 (Suppl.): 42S-45S. RV
83. Cutler JA, Follman D, Alexander PS. Randomised controlled trials of sodium reduction: an overview. Am J Clin Nutr. 1997; 65 (Suppl. 2): 643S-651S. MA
84. Beckmann SL, Os I, Kjeldsen SE, Eide IK, Westheim AS, Hjermann I. Effect of dietary counselling on blood pressure and arterial plasma catecholamines in primary hypertension. Am J Hypertens. 1995; 8: 704-711. OS
85. Margetts BM, Beilin LJ, Vandongen R, Armstrong BK. Vegetarian diet in mild hypertension: a randomised controlled trial. Brit Med J. 1986; 293: 1468-1471. RT (Pubitemid 17190313)
86. Bao DQ, Mori TA, Burke V, Puddey IB, Beilin LJ. Effects of dietary fish and weight reduction on ambulatory blood pressure in overweight hypertensives. Hypertension. 1998; 32: 710-717. RT (Pubitemid 28480549)
87. Sacks FM, Svetkey LP, Vollmer WM, Appel LJ, Bray GA, Harsha D et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH Sodium Collaborative Research Group. N Engl J Med. 2001; 344: 3-10. RT
88. Collins R, MacMahon S. Blood pressure, antihypertensive drug treatment and the risk of stroke and of coronary heart disease. Br Med Bull. 1994; 50: 272-298. MA (Pubitemid 24165020)
89. Staessen JA, Gasowski J, Wang JG, Thijs L, Den Hond E, Boissel JP et al. Risks of untreated and treated isolated systolic hypertension in the elderly: metaanalysis of outcome trials. Lancet. 2000; 355: 865-872. MA (Pubitemid 30137665)
90. Thijs L, Fagard R, Lijnen P, Staessen J, Van Hoof R, Amery A. A metaanalysis of outcome trials in elderly hypertensives. J Hypertens. 1992; 10: 1103-1109. MA
91. Gueyffier F, Boutitie F, Boissel JP, Pocock S, Coope J, Cutler J et al. The effect of antihypertensive drug treatment on cardiovascular outcomes in women and men. Results from a metaanalysis of individual patient data in randomised controlled trials. Ann Intern Med. 1997; 126: 761-767. MA
92. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or Calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT). JAMA. 2002; 288: 2981-2997. RT
93. Zanchetti A, Bond MG, Hennig M, Neiss A, Mancia G, Dal Palu C et al. Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: Principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation. 2002; 106: 2422-2427. RT (Pubitemid 35278796)
94. Borhani NO, Mercuri M, Borhani PA, Buckalew VM, Canossa-Terris M, Carr AA et al. Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS). A randomized controlled trial. JAMA. 1996; 276: 785-791. RT
95. National Intervention Cooperative Study in Elderly Hypertensives Study Group. Randomized double-blind comparison of a Calcium antagonist and a diuretic in elderly hypertensives. Hypertension. 1999; 34: 1129-1133. RT
96. Hansson L, Lindholm LH, Ekbom T, Dahlöf B, Lanke J, Schersten B et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity in the Swedish Trial in Old Patients with Hypertension-2 Study. Lancet. 1999; 354: 1751-1756. RT
97. Hansson L, Hedner T, Lund-Johansen P, Kjeldsen SE, Lindholm LH, Syvertsen JO et al. Randomised trial of effects of Kalzium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet. 2000; 356: 359-365. RT (Pubitemid 30487491)
98. Agabiti Rosei E, Dal Palu C, Leonetti G, Magnani B, Pessina A, Zanchetti A for the VHAS investigators. Clinical results of the Verapamil in Hypertension and Atherosclerosis Study. J Hypertens. 1997; 15: 1337-1344. RT
99. Brown MJ, Palmer CR, Castaigne A, de Leeuw PW, Mancia G, Rosenthal T et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet. 2000; 356: 366-372. RT (Pubitemid 30487492)
100. Black HR, Elliot WJ, Grandist G, Grambsch P, Lucente T, White WBet al. for the CONVINCE Research Group. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular Endpoints (CONVINCE) trial. JAMA. 2003; 289: 2073-2082. RT
101. Staessen JA, Wang J, Thijs L. Cardiovascular prevention and blood pressure reduction: a qualitative overview updated until 1 March. 2003. J Hypertens. 2003; 21: 1055-1076. MA (Pubitemid 36667856)
102. Blood Pressure Lowering Treatment Trialists Collaboration. Effects of different blood pressure-lowering regimens on major cardiovascular events: results of prospectively designed overviews of randomised trials. Lancet. 2003; 362: 1527-1535. MA
103. Dahlöf B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-Deutsche BPLA): a multicentre randomised controlled trial. Lancet. 2005; 366: 895-906. RT (Pubitemid 41265663)
104. Pepine CJ, Handberg EM, Cooper-De Hoff RM, Marks RG, Kowey P, Messerli FH et al. Acalcium antagonist vs a noncalcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil- Trandolapril Study (INVEST): a randomized controlled trial. JAMA. 2003; 290: 2805-2816.
105. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in Type 2 diabetes: UKPDS 39. BMJ. 1998; 317: 713-720. RT
106. Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A et al. Effect of angiotensinconverting enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet. 1999; 353: 611-616. RT (Pubitemid 29087980)
107. Wing LMH, Reid CM, Ryan P, Beilin LJ, Brown MA, Jennings GLR et al. A comparison of outcomes with angiotensin-converting enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med. 2003; 348: 583-592. RT (Pubitemid 36204952)
108. Lithell H, Hansson L, Skogg I, Elmfeldt D, Hofman A, Olofsson B et al. for the SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE). Principal results of a randomised double-blind intervention trial. J Hypertens. 2003; 21: 875-886. RT (Pubitemid 36677151)
109. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002; 359: 995-1003. RT (Pubitemid 34286536)
110. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004; 363: 2022-2031. RT (Pubitemid 38781102)
111. Mochizuki S, Dahlöf B, Shimizu M, Ikewaki K, Yoshikawa M, Taniguchi I et al. Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomized, open-label, blinded endpoint morbidity-mortality study. Lancet. 2007; 369: 1431-1439. RT (Pubitemid 46635780)
112. Schrader J, Lüders S, Kulschewski A, Hammersen F, Plate K, Berger J et al. Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention: principal results of a prospective randomized controlled study (MOSES). Stroke. 2005; 36: 1218-1226. RT (Pubitemid 40798742)
113. The ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008; 358: 1547-1559. RT
114. Williams B, Lacy PS, Thom SM, Cruickshank K, Stanton A, Collier D et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes. Principal results of the Conduit Artery Function Evaluation (CAFÉ) Study. Circulation. 2006; 113: 1213-1225. RT
115. Lindholm LH, Carlberg B, Samuelsson O. Should β blockers remain first choice in the treatment of primary hypertension? A metaanalysis. Lancet. 2005; 366: 1545-1553. MA (Pubitemid 41540112)
116. Hypertension. Management of hypertension in adults in primary care. NICE/BHS. June. 2006. www.nice.org.uk/CG034. GL
117. Schmieder RE, Schlaich MF, Klingbeil AU, Martus P. Update on reversal of left ventricular hypertrophy in essential hypertension (a metaanalysis of all randomized double-blind studies until December 1998). Nephrol Dial Transplant. 1998; 13: 564-569. MA (Pubitemid 28119033)
118. Gosse P, Sheridan DJ, Zannad F, Dubourg O, Gueret P, Karpov Y et al. Regression of left ventricular hypertrophy in hypertensive patients treated with indapamide SR 1.5 mg versus enalapril 20 mg; the LIVE study. J Hypertens. 2000; 18: 1465-1475. RT
119. Terpstra WL, May JF, Smit AJ, de Graeff PA, Havinga TK, van der Veur E et al. Long-term effects of amlodipine and lisinopril on left ventricular mass and diastolic function in elderly, previously untreated hypertensive patients: the ELVERA trial. J Hypertens. 2001; 19: 303-309. RT
120. Devereux RB, Palmieri V, Sharpe N, De Quattro V, Bella JN, de Simone G et al. Effects of once-daily angiotensin-converting enzyme inhibition and calcium channel blockade-based antihypertensive treatment regimens on left ventricular hypertrophy and diastolic filling in hypertension. The Prospective Randomized Enalapril Study Evaluating Regression of Ventricular Enlargement (PRESERVE) trial. Circulation. 2001; 104: 1248-1254. RT
121. Cuspidi C, Muiesan ML, Valagussa L, Salvetti M, Di Biagio C, Agabiti-Rosei E et al. on behalf of the CATCH investigators. Comparative effects of candesartan and enalapril on left ventricular hypertrophy in patients with essential hypertension: the Candesartan Assessment in the Treatment of Cardiac Hypertrophy (CATCH) study. J Hypertens. 2002; 20: 2293-2300. RT (Pubitemid 35388249)
122. Agabiti Rosei E, Trimarco B, Muiesan ML, Reid J, Salvetti A, Tang R et al. Cardiac structural and functional changes during long-term antihypertensive treatment with lacidipine and atenolol in the European Lacidipine Study on Atherosclerosis (ELSA). J Hypertens. 2005; 23: 1091-1098. RT (Pubitemid 40637930)
123. Thurmann PA, Kenedi P, Schmidt A, Harder S, Rietbrock N. Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension. Circulation. 1998; 98: 2037-2042. RT (Pubitemid 28512229)
124. Malmqvist K, Kahan T, Edner M, Held C, Hagg A, Lind L et al. Regression of left ventricular hypertrophy in human hypertension with irbesartan. J Hypertens. 2001; 19: 1167-1176. RT (Pubitemid 32493652)
125. Dahlöf B, Zanchetti A, Diez J, Nicholls MG, Yu CM, Barrios V et al. Effects of losartan and atenolol on left ventricular mass and neurohormonal profile in patients with essential hypertension and left ventricular hypertrophy. J Hypertens. 2002; 20: 1855-1864. RT
126. Perlini S, Muiesan ML, Cuspidi C, Sampieri L, Trimarco B, Aurigemma GP et al. Midwall mechanics are improved after regression of hypertensive left ventricular hypertrophy and normalization of chamber geometry. Circulation. 2001; 103: 678-683. OS (Pubitemid 32144196)
127. Levy D, Salomon M, DAgostino RB, Belanger AJ, Kannel WB. Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy. Circulation. 1994; 90: 1786-1793. OS (Pubitemid 24320926)
128. Mathew J, Sleight P, Lonn E, Johnstone D, Pogue J, Yi Q et al. Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. Circulation. 2001; 104: 1615-1621. RT (Pubitemid 32947523)
129. Muiesan ML, Salvetti M, Rizzoni D, Castellano M, Donato F, Agabiti-Rosei E. Association of change in left ventricular mass with prognosis during long-term antihypertensive treatment. J Hypertens. 1995; 13: 1091-1095. OS
130. Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Gattobigio R, Zampi I et al. Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation. 1998; 97: 48-54. OS (Pubitemid 28036154)
131. Pitt B, Byington RP, Furberg CD, Hunninghake DB, Mancini GBJ, Miller ME et al. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. Circulation. 2000; 102: 1503-1510. RT
132. Zanchetti A, Agabiti Rosei E, Dal Palu C, Leonetti G, Magnani B, Pessina A. TheVerapamil in Hypertension and Atherosclerosis Study (VHAS): results of long-term randomized treatment with either verapamil or chlorthalidone on carotid intimamedia thickness. J Hypertens. 1998; 16: 1667-1676. RT (Pubitemid 28515494)
133. Simon A, Gariépy J, Moyse D, Levenson J. Differential effects of nifedipine and co-amilozide on the progression of early carotid wall changes. Circulation. 2001; 103: 2949-2954. RT (Pubitemid 32578133)
134. MacMahon S, Sharpe N, Gamble G, Clague A, Mhurchu CN, Clark T et al. Randomized, plazebo-controlled trial of the angiotensin-converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial disease. J Am Coll Cardiol. 2000; 36: 438-443. RT (Pubitemid 30624005)
135. Lonn EM, Yusuf S, Dzavik V, Doris CI, Yi Q, Smith S et al. Effects of ramipril and vitamin E on atherosclerosis: The Study to Evaluate Carotid Ultrasound changes in patients treated with Ramipril and vitamin E (SECURE). Circulation. 2001; 103: 919-925. RT (Pubitemid 32183795)
136. Zanchetti A, Crepaldi G, Bond G, Gallus G, Veglia F, Mancia G et al. Different effects of antihypertensive regimens based on fosinopril or hydrochlorothiazide with or without lipid lowering by pravastatin on progression of asymptomatic carotid atherosclerosis. Principal results of PHYLLIS - a randomized double-blind trial. Stroke. 2004; 35: 2807-2812. RT
137. Lindholm LH, Ibsen H, Borch-Johnsen K, Olsen MH,Wachtell K, Dahlöf B et al. Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. J Hypertens. 2002; 20: 1879-1886. RT
138. DREAM Trial Investigators. Effect of ramipril on the incidence of diabetes. N Engl J Med. 2006; 355: 1551-1562. RT
139. Opie LH, Schall R. Old antihypertensives and new diabetes. J Hypertens. 2004; 22: 1453-1458. MA (Pubitemid 39037590)
140. Mancia G, Grassi G, Zanchetti A. New-onset diabetes and antihypertensive drugs. J Hypertens. 2006; 24: 3-10. MA (Pubitemid 41819128)
141. Elliot WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet. 2007; 369: 201-207. MA
142. Verdecchia P, Reboldi G, Angeli F, Borgioni C, Gattobigio R, Filippucci L et al. Adverse prognostic significance of new diabetes intreated hypertensive subjects. Hypertension. 2004; 43: 963-969. OS (Pubitemid 38579899)
143. Kostis JB, Wilson AC, Freudenberger RS, Cosgrove NM, Pressel SL, Davis BR. Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes. Am J Cardiol. 2005; 95: 29-35. CT
144. Heidenreich PA, Mc Donald KM, Hastie T, Fadel B, Hagan V, Lee BK et al. Meta-analysis of trials comparing β-blockers, calcium antagonists, and nitrates for stable angina. JAMA. 1999; 281: 1927-1936. MA (Pubitemid 29242807)
145. Shekelle PG, Rich MW, Morton SC, Atkinson CS, Tu W, Maglione M et al. Efficacy of angiotensin-converting enzyme inhibitors and β-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials. J Am Coll Cardiol. 2003; 41: 1529-1538. MA (Pubitemid 36543372)
146. Freemantle N, Cleland J, Young P, Mason J, Harrison J. β blockade after myocardial infarction: systematic review and meta regression analysis. Br Med J. 1999; 318: 1730-1737. MA (Pubitemid 29290470)
147. Sharma AM, Pischon T, Hardt S, Kunz I, Luft FC. Hypothesis: β-adrenergic receptor blockers and weight gain: a systematic analysis. Hypertension. 2001; 37: 250-254. RV (Pubitemid 32199083)
148. Van Zwieten PA. Centrally acting antihypertensive drugs. In: ManciaG, Chalmers J, Julius S, Saruta T, Weber M (Editors). Manual of Hypertension. London: Churchill Livingston; 2002. p. 401-410. RV
149. Zannad F. Aldosterone therapy in resistant hypertension. J Hypertens. 2007; 25: 747-750. RV (Pubitemid 46398868)
150. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT). JAMA. 2000; 283: 1967-1975. RT
151. Gradman AH, Schmieder RE, Lins RL, Nussberger J, Chang Y, Bedigian MP. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and plazebo-like tolerability in hypertensive patients. Circulation. 2005; 111: 1012-1018. RT (Pubitemid 40354519)
152. Villamil A, Chrysant SG, Calhoun D, Schober B, Hau H, Matrisciano-Dimichino L et al. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J Hypertens. 2007; 25: 217-226. RT
153. OBrien E, Barton J, Nussberger J, Mulcahy D, Jensen C, Dicker P et al. Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker. Hypertension. 2007; 49: 276-284. RT (Pubitemid 46143002)
154. Burke TA, Sturkenboom MC, Lu S,Wentworth CE, Lin Y, Rhoads GG. Discontinuation of antihypertensive drugs among newly diagnosed hypertensive patients in UK general practice. J Hypertens. 2006; 24: 1193-1200. OS (Pubitemid 43772328)
155. Gueyffier F, Bulpitt C, Boissel JP, Schron E, Ekbom T, Fagard R et al. Antihypertensive drugs in very old people: a subgroup analysis of randomised controlled trials. Lancet. 1999; 353: 793-796. MA (Pubitemid 29110404)
156. Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008; 358: 1887-1898. RT
157. Messerli FH, Grossman E, Goldbourt U. Are beta-blockers efficacious as first-line therapy for hypertension in the elderly? JAMA. 1998; 279: 1903-1907. MA.
158. Gong L, ZhangW, Zhu Y, Zhu J, Kong D, Page V et al. Shanghai trial of nifedipine in the elderly (STONE). J Hypertens. 1996; 16: 1237-1245. CT (Pubitemid 26343504)
159. Liu L, Wang JL, Gong L, Liu G, Staessen JA, for the Syst-China Collaborative Group. Comparison of active treatment and plazebo in older Chinese patients with isolated systolic hypertension. J Hypertens. 1998; 16: 1823-1829. CT
160. Kjeldsen SE, Dahlöf B, Devereux RB, Julius S, Aurup P, Edelman J et al. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy. JAMA. 2002; 288: 1491-1498. RT
161. Somes GW, Pahor M, Shorr RI, Cushman WC, Applegate WB. The role of diastolic blood pressure when treating isolated systolic hypertension. Arch Int Med. 1999; 159: 2004-2009. RT (Pubitemid 29453587)
162. Fagard RH, Staessen JA, Thijs L, Celis H, Bulpitt CJ, de Leeuw PW et al. On-treatment diastolic blood pressure and prognosis in systolic hypertension. Arch Intern Med. 2007; 167: 1884-1891. RT (Pubitemid 47481484)
163. Tarnow L, Rossing P, Gall MA, Nielsen FS, Parving HH. Prevalence of arterial hypertension in diabetic patients before and after the JNC-V. Diabetes Care. 1994; 17: 1247-1251. OS (Pubitemid 24324966)
164. Epstein M, Sowers JR. Diabetes mellitus and hypertension. Hypertension. 1992; 19: 403-418. RV
165. Grossman E, Messerli FH. Diabetic and hypertensive heart disease. Ann Intern Med. 1996; 125: 304-310. RV (Pubitemid 126449277)
166. Dinneen SF, Gerstein HC. The association of microalbuminuria and mortality in noninsulin-dependent diabetes mellitus. A systematic overview of the literature. Arch Intern Med. 1997; 157: 1413-1418. MA
167. Mogensen CE. Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy. BMJ. 1982; 285: 685-688. RT
168. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med. 1993; 329: 1456-1462. RT
169. Blood Pressure Lowering Treatment Trialists Collaboration. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus. Results of prospectively designed overviews and randomized trials. Arch Int Med. 2005; 165: 1410-1419. MA
170. Ryden L, Standl E, Bartnik M, Van den Berghe G, Betteridge J, de Boer MJ et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. Eur Heart J. 2007; 28: 88-136. GL
171. Parving HH, Hommel E, Jensen BR, Hansen HP. Long-term beneficial effect of ACE-inhibition on diabetic nephropathy in normotensive Type 1 diabetic patients. Kidney Int. 2001; 60: 228-234. OS (Pubitemid 32587558)
172. Ruggenenti P, Fassi A, Ilieva AP, Bruno S, Iliev IP, Brusegan V et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med. 2004; 351: 1941-1951. RT (Pubitemid 39447135)
173. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised plazebo-controlled trial. Lancet. 2004; 364: 685-696. RT
174. PATS Collaborative Group. Post-stroke antihypertensive treatment study. Clin Med J. 1995; 108: 710-717. RT
175. Trenkwalder P, Elmfeldt D, Holman A, Lithell H, Olofsson B, Papademetriou V et al. The Study on Cognition and Prognosis in the Elderly (SCOPE) - major cardiovascular events and stroke in subgroups of patients. Blood Press. 2005; 14: 31-37. CT (Pubitemid 40443751)
176. Schrader J, Luders S, Kulschewski A, Berger J, Zidek W, Treib J et al. The ACCESS Study: evaluation of acute candesartan cilexetil therapy in stroke survivors. Stroke. 2003; 34: 1699-1703. RT (Pubitemid 36842630)
177. Skoog I, Lernfelt B, Landahl S, Palmertz B, Andreasson LA, Nilsson L et al. 15-year longitudinal study of blood pressure and dementia. Lancet. 1996; 347: 1141-1145. OS (Pubitemid 26127022)
178. Kilander L, Nyman H, Boberg M, Hansson L, Lithell H. Hypertension is related to cognitive impairment: A20 year follow-up of 999 men. Hypertension. 1998; 31: 780-788. OS (Pubitemid 28108576)
179. Launer LJ, Masaki K, Petrovitch H, Foley D, Havlik RJ. The association between midlife blood pressure levels and late-life cognitive function. The Honolulu-Asia Aging Study. JAMA. 1995; 274: 1846-1851. OS
180. Vermeer SE, Prins ND, den Heijer T, Hofman A, Koudstaal PJ, Breteler MM. Silent brain infarcts and risk of dementia and cognitive decline. NEngl J Med. 2003; 348: 1215-1222. OS (Pubitemid 36359297)
181. Birna J, Morris R, Donaldson N, Kalra L. The effects of blood pressure reduction on cognitive function: a review of effects based on pooled data from clinical trials. J Hypertens. 2006; 24: 1907-1914. MA (Pubitemid 44371252)
182. Kannel WB. Risk stratification in hypertension: new insights from the Framingham study. Am J Hypertens. 2000; 13 (Suppl. 1): 3-10. OS
183. Domanski MJ, Mitchell GF, Norman JE, Exner DV, Pitt B, Pfeffer MA. Independent prognostic information provided by sphygmomanometrically determined pulse pressure and mean arterial pressure in patients with left ventricular dysfunction. J Am Coll Cardiol. 1999; 33: 951-958. OS
184. Yap YG, Duong T, Bland JM, Malik M, Torp-Pederson C, Kober L, Connolly SJ et al. Prognostic value of blood pressure measured during hospitalization after acute myocardial infarction: an insight from survival trials. J Hypertens. 2007; 25: 307-313. OS (Pubitemid 46071928)
185. Freemantle N, Cleland J, Young P, Mason J, Harrison J. β blockade after myocardial infarction: systematic review and meta regression analysis. Br Med J. 1999; 318: 1730-1737. RV (Pubitemid 29290470)
186. Dickstein K, Kjekshus J. Steering Committee of the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet. 2002; 360: 752-760. RT
187. Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Kober L, Maggioni AP et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003; 349: 1893-1896. RT (Pubitemid 37409706)
188. Shekelle PG, Rich MW, Morton SC, Atkinson CS, Tu W, Maglione M et al. Efficacy of angiotensin-converting enzyme inhibitors and β-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials. J Am Coll Cardiol. 2003; 41: 1529-1538. MA (Pubitemid 36543372)
189. Lee VC, Rhew DC, Dylan M, Badamgarav E, Braunstein GD, Weingarten SR. Meta-analysis: angiotensin-receptor blockers in chronic heart failure and high-risk acute myocardial infarction. Ann Intern Med. 2004; 141: 693-704. MA (Pubitemid 39434842)
190. Metra M, Ponikowski P, Dickstein K, McMurray JJV, Gavazzi A, Bergh CH et al. Advanced chronic heart failure: A position statement from the Study Group on Advanced Heart Failure of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2007; 9: 684-694. GL (Pubitemid 46705572)
191. Packer M, OConnor CM, Ghali JK, Pressler ML, Carson PE, Belkin RN et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med. 1996; 335: 1107-1114. RT (Pubitemid 26330964)
192. Cohn JN, Ziesche S, Smith R, Anand I, Dunkman B, Loeb H et al. Effect of the Calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril - V-HeFT III. Circulation. 1997; 96: 856-863. RT (Pubitemid 27329620)
193. Solomon SD, Janardhanan R, Verma A, Bourgoun M, Daley WL, PurkayasthaDet al. Effect of angiotensin receptor blockade and antihypertensive drugs on diastolic function in patients with hypertension and diastolic dysfunction: a randomised trial. Lancet. 2007; 369: 2079-2087. RT
194. Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol. 1998; 82: 2N-9N. OS (Pubitemid 28507114)
195. Hankey GJ. Preventable stroke and stroke prevention. J Thromb Haemost. 2005; 3: 1638-1645. RV
196. Verdecchia P, Reboldi G, Gattobigio R, Bentivoglio M, Borgioni C, Angeli F et al. Atrial fibrillation in hypertension: predictors and outcome. Hypertension. 2003; 41: 218-223. OS (Pubitemid 36204892)
197. Lip GY, Frison L, Grind M. Effect of hypertension on anticoagulated patients with atrial fibrillation. Eur Heart J. 2007; 28: 752-759. OS (Pubitemid 46439230)
198. Aksnes TA, Flaa A, Strand A, Kjeldsen SE. Prevention of new-onset atrial fibrillation and its predictors with angiotensin II-receptor blockers in the treatment of hypertension and heart failure. J Hypertens. 2007; 25: 15-23. CT
199. Wachtell K, Lehto M, Gerdts E, Olsen MH, Hornestam B, Dahlof B et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol. 2005; 45: 712-719. RT (Pubitemid 40282586)
200. Madrid AH, Bueno MG, Rebollo JM, Marin I, Pena G, Bernal E et al. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective, randomized study. Circulation. 2002; 106: 331-336. RT
201. Fogari R, Mugellini A, DestroM, Corradi L, Zoppi A, Fogari E et al. Losartan and prevention of atrial fibrillation recurrence in hypertensive patients. J Cardiovasc Pharmacol. 2006; 47: 46-50. CT (Pubitemid 44378223)
202. Healey JS, Baranchuk A, Crystal E, Morillo Ca, Garfinkle M, Yusuf S et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol. 2005; 45: 1832-1839. MA (Pubitemid 40789940)
203. National High Blood Pressure Education Program Working Group. Report on high blood pressure in pregnancy. Am J Obstet Gynecol. 1990; 163: 1691-1712. GL
204. Levine RJ, Ewell MG, Hauth JC, Curet LB, Catalano PM, Morris CD, Choudhary G, Sibai BM. Should the definition of preeclampsia include a rise in diastolic blood pressure of ≥ 15 mmHg to a level < 90 mmHg in association with proteinuria? Am J Obstet Gynecol. 2000; 183: 787-792. GL
205. Brown MA, Lindheimer MD, de Swiet M, Van AA, Moutquin JM. The classification and diagnosis of the hypertensive disorders of pregnancy: statement from the International Society for the Study of Hypertension in Pregnancy (ISSHP). Hypertens Pregnancy. 2001; 20: IX-XIV. GL
206. Helewa ME, Burrows RF, Smith J, Williams K, Brain P, Rabkin SW. Report of the Canadian Hypertension Society Consensus Conference: 1. Definitions, evaluation and classification of hypertensive disorders in pregnancy. Can Med Assoc J. 1997; 157: 715-725. GL
207. Sibai BM, Mabie WC, Shamsa F, Villar MA, Anderson GD.Acomparison of no medication versus methyldopa or labetalol in chronic hypertension during pregnancy. Am J Obstet Gynecol. 1990; 162: 960-966. RT (Pubitemid 20155414)
208. Gruppo di Studio Ipertensione in Gravidanza. Nifedipine versus expectant management in mild to moderate hypertension in pregnancy. Br J Obstet Gynaecol. 1998; 105: 718-722. RT
209. Atallah AN, Hofmeyr GJ, Duley L. Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems. Cochrane Database Syst Rev. 2000; 2: CD001059. RV
210. Olsen SF, Secher NJ, Tabor A, Weber T, Walker JJ, Gluud C. Randomised clinical trials of fish oil supplementation in high risk pregnancies. Fish Oil Trials In Pregnancy (FOTIP) Team. Br J Obstet Gynaecol. 2000; 107: 382-395. MA
211. Knight M, Duley L, Henderson-Smart DJ, King JF. Antiplatelet agents for preventing and treating pre-eclampsia. Cochrane Database Syst Rev. 2000; 2: CD000492. RV
212. Khedun SM, Moodley J, Naicker T, Maharaj B. Drug management of hypertensive disorders of pregnancy. Pharmacol Ther. 1997; 74: 221-258. RV (Pubitemid 27337349)
213. de Swiet M. Maternal blood pressure and birthweight. Lancet. 2000; 355: 81-82. OS
214. von Dadelszen P, OrnsteinMP, Bull SB, Logan AG, Koren G, Magee LA. Fall in mean arterial pressure and fetal growth restriction in pregnancy hypertension: a meta-analysis. Lancet. 2000; 355: 87-92. MA
215. Report of the National High Blood Pressure Education Program Working Group on high blood pressure in pregnancy. Am J Obstet Gynecol. 2000; 183: S1-S22. GL
216. Dekker G, Sibai B. Primary, secondary, and tertiary prevention of pre-eclampsia. Lancet. 2001; 357: 209-215. GL (Pubitemid 32108113)
217. Magee LA, Cham C, Waterman EJ, Ohlsson A, von Dadelszen P. Hydralazine for treatment of severe hypertension in pregnancy: meta-analysis. Brit Med J. 2003; 327: 955-960. MA (Pubitemid 37330398)
218. Kyle PM, Redman CW. Comparative risk-benefit assessment of drugs used in the managementof hypertension in pregnancy. Drug Saf. 1992; 7: 223-234. RV
219. NIH: National High Blood Pressure Education Program - Working Group Report on High Blood Pressure in Pregnancy. NIH Publication No. 00-3029, 2000, 2000, GL.
220. Magee LA, Elran E, Bull SB, Logan A, Koren G. Risks and benefits of beta-receptor blockers for pregnancy hypertension: overview of the randomized trials. Eur J Obstet Gynecol Reprod Biol. 2000; 88: 15-26. RV (Pubitemid 30009366)
221. Magee LA, Ornstein MP, von Dadelszen P. Fortnightly review: management of hypertension in pregnancy. Br Med J. 1999; 318: 1332-1336. RV
222. Ismail AA, Medhat I, Tawfic TA, Kholeif A. Evaluation of Calcium-antagonist (Nifedipine) in the treatment of pre-eclampsia. Int J Gynaecol Obstet. 1993; 40: 39-43. RT (Pubitemid 23056252)
223. Sibai BM, Barton JR, Akl S, Sarinoglu C, Mercer BM. A randomized prospective comparison of nifedipine and bed rest versus bed rest alone in the management of preeclampsia remote from term. Am J Obstet Gynecol. 1992; 167: 879-884. RT
224. Marlettini M, Crippa S, Morselli-Labate A, Contarini A, Orlandi C. Randomized comparison of Calcium antagonists and β-blockers in the treatment of pregnancy-induced hypertension. Curr Ther Res. 1990; 45: 684-694. RT (Pubitemid 20381580)
225. Magee LA, Miremadi S, Li J, Cheng C, Ensom MH, Carleton B. et al. Therapy with both magnesium sulfate and nifedipine does not increase the risk of serious magnesium-related maternal side effects in women with preeclampsia. Am J Obstet Gynecol. 2005; 193: 153-163. CT (Pubitemid 40991839)
226. Cooper WO, Hernandez-Diaz S, Arbogast PG, Dudley JA, Dyer S, Gideon PS et al. Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J Med. 2006; 354: 2443-12251 CT (Pubitemid 43855047)
227. Altman D, Carroli G, Duley L, Farrell B, Moodley J, Neilson J, Smith D. Do women with preeclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomised plazebo-controlled trial. Lancet. 2002; 359: 1877-1890. RT (Pubitemid 34615765)
228. Beardmore KS, Morris JM, Gallery ED. Excretion of antihypertensive medication into human breast milk: a systematic review. Hypertens Pregnancy. 2002; 21: 85-95. RV
229. ParadisiG, Biaggi A, Savone R, Ianniello F, Tomei C, Caforio L et al. Cardiovascular risk factors in healthy women with previous gestational hypertension. J Clin Endocrinol Metab. 2006; 91: 1233-1238. OS
230. Wilson BJ, Watson MS, Prescott GJ, Sunderland S, Campbell DM, Hannaford P et al. Hypertensive diseases of pregnancy and risk of hypertension and stroke in later life: results from cohort study. Br Med J. 2003; 326: 845-851. OS (Pubitemid 36461414)
231. Casas JP, Chua W, Lukogeorgakis S, Vallance P, Smeeth L, Hingorani AD et al. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and metaanalysis. Lancet. 2005; 366: 2026-2033. MA (Pubitemid 41773378)
232. Brenner BM, Cooper ME, De Zeeuw D, Keane WF, Mitch WE, Parving HH et al. Effects of losartan on renal and cardiovascular outcomes in patients with Type 2 diabetes and nephropathy. N Engl J Med. 2001; 345: 861-869. RT
233. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to Type 2 diabetes. N Engl J Med. 2001; 345: 851-860. RT
234. Parving H-H, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with Type 2 diabetes. N Engl J Med. 2001; 345: 870-878. RT
235. Schjoedt KJ, Rossing K, Juhl TR, Boomsma F, Tarnow L, Rossing P et al. Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy. Kidney Int. 2006; 70: 536-542. RT (Pubitemid 44141580)
236. Voyaki SM, Staessen JA, Thijs L,Wang JG, Efstratopoulos AD, Birkenhager WH et al. Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Follow-up of renal function in treated and untreated older patients with isolated systolic hypertension. Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. J Hypertens. 2001; 19: 511-519. RT
237. Agodoa LY, Appel L, Bakris GL, Beck G, Bourgoignie J, Briggs JP et al. for the African American Study of Kidney Disease and Hypertension (AASK) Study Group. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis. A randomized controlled trial. JAMA. 2001; 285: 2719-2728. RT
238. Rahman M, Pressel S, Davis BR, Nwachuku C, Wright JT Jr, Whelton PK et al. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a Calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med. 2005; 165: 936-946. CT (Pubitemid 40563242)
239. Wright JT, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J et al. for the African American Study of Kidney Disease and Hypertension Study Group. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK Trial. JAMA. 2002; 288: 2421-2431. RT
240. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascularand microvascular complications in Type 2 diabetes: UKPDS 39. BMJ. 1998; 317: 713-720. RT
241. Barnett AH. Preventing renal complications in diabetic patients: the Diabetics Exposed to Telmisartan And enalaprIL (DETAIL) study 1. Acta Diabetol. 2005; 42 (Suppl. 1): S42-S49. RT
242. Ibsen H, Olsen MH,Wachtell K, Borch-Johnsen K, Lindholm LH, Mogensen CE et al. Does albuminuria predict cardiovascular outcomes on treatment with losartan versus atenolol in patients with diabetes, hypertension, and left ventricular hypertrophy? The LIFE study. Diabetes Care. 2006; 29: 595-600. CT (Pubitemid 44115360)
243. Viberti G, Wheeldon NM. MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators. Microalbuminuria reduction with valsartan in patients with Type 2 diabetes mellitus: a blood pressure independent effect. Circulation. 2002; 106: 672-678. RT
244. Vogt L, Navis G, Koster J, Manolis AJ, Reid JL, de Zeeuw D et al. The angiotensin II receptor antagonist telmisartan reduces urinary albumin excretion in patients with isolated systolic hypertension: results of a randomized, double-blind, placebo-controlled trial. J Hypertens. 2005; 23: 2055-2061. RT (Pubitemid 41830402)
245. White WB, Duprez D, St Hillaire R, Krause S, Roniker B, Kuse-Hamilton J et al. Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. Hypertension. 2003; 41: 1021-1026. RT (Pubitemid 36548598)
246. Dalla Vestra M, Pozza G, Mosca A, Grazioli V, Lapolla A, Fioretto P et al. Effect of lercanidipine compared with ramipril on albumin excretion rate in hypertensive Type 2-diabetic patients with microalbuminuria: DIAL study. Diabetes Nutr Metab. 2004; 17: 259-266. RT
247. Marre M, Puig JG, Kokot F, Fernandez M, Jermendy G, Opie L et al. Equivalence of indapamide SR and enalapril on microalbuminuria reduction in hypertensive patients with Type 2 diabetes: the NESTOR Study. J Hypertens. 2004; 22: 1613-1622. RT (Pubitemid 39037614)
248. Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T. Combination treatment of angiotensin- II receptor blocker and angiotensinconverting enzyme inhibitor in nondiabetic renal disease (COOPERATE): a randomised controlled trial. Lancet. 2003; 361: 117-124. RT (Pubitemid 36092015)
249. Mogensen CE, Neldam S, Tikkanen I, Oren S, Viskoper R,Watts RWet al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and noninsulin-dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. Br Med J. 2000; 321: 1440-1444. RT
250. Kincaid-Smith P, Fairley K, Packham D. Randomized controlled crossover study of the effect on proteinuria and blood pressure of adding an angiotensin II receptor antagonist to an angiotensin converting enzyme inhibitor in normotensive patients with chronic renal disease and proteinuria. Nephrol Dial Transplant. 2002; 17: 597-601. RT (Pubitemid 34308813)
251. Andersen NH, Poulsen PL, Knudsen ST, Poulsen SH, Eiskjaer H, Hansen KW et al. Long-term dual blockade with candesartan and lisinopril in hypertensive patients with diabetes: the CALM II study. Diabetes Care. 2005; 28: 273-277. RT (Pubitemid 40170925)
252. MacKinnon M, Shurraw S, Akbari A, Knoll GA, Jaffey J, Clark HD. Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: a systematic review of the efficacy and safety data. Am J Kidney Dis. 2006; 48: 8-20. MA (Pubitemid 43912958)
253. Rossing K, Schjoedt KJ, Jensen BR, Boomsma F, Parving HH. Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria. Kidney Int. 2005; 68: 1190-1198. RT (Pubitemid 43246436)
254. Schmieder RE, Klingbeil AU, Fleischmann EH, Veelken R, Delles C. Additional antiproteinuric effect of ultrahigh dose candesartan: a double-blind, randomized, prospective study. J Am Soc Nephrol. 2005; 16: 3038-3045. RT
255. Segura J, Ruilope LM, Zanchetti A. On the importance of estimating renal function for cardiovascular risk assessment. J Hypertens. 2004; 22: 1635-1639. RV (Pubitemid 39141949)
256. Dekker JM, Girman C, Rhodes T, Nijpels G, Stehouwer CD, Bouter LM et al. Metabolic syndrome and 10-year cardiovascular disease risk in the Hoorn Study. Circulation. 2005; 112: 666-673. OS (Pubitemid 41099045)
257. Schmidt MI, Duncan BB, Bang H, Pankow JS, Ballantyne CM, Golden SH et al. Identifying individuals at high risk for diabetes: The Atherosclerosis Risk in Communities study. Diabetes Care. 2005; 28: 2013-2018. OS (Pubitemid 41060977)
258. Cuspidi C, Meani S, Fusi V, Severgnini B, Valerio C, Catini E et al. Metabolic syndrome and target organ damage in untreated essential hypertensives. J Hypertens. 2004; 22: 1991-1998. OS (Pubitemid 39336683)
259. Schillaci G, Pirro M, Vaudo G, Mannarino MR, Savarese G, Pucci G et al. Metabolic syndrome is associated with aortic stiffness in untreated essential hypertension. Hypertension. 2005; 45: 1978-1982. OS (Pubitemid 40770308)
260. Schillaci G, Pirro M, Pucci G, Mannarino MR, Gemelli F, Siepi D et al. Different impact of the metabolic syndrome on left ventricular structure and function in hypertensive men and women. Hypertension. 2006; 47: 881-886. OS (Pubitemid 44297559)
261. Krauss RM, Eckel RH, Howard B, Appel LJ, Daniels SR, Deckelbaum RJ et al. AHA Dietary Guidelines: revision. 2000: Astatement for healthcare professionals from the Nutrition Committee of the American Heart Association. Circulation. 2000; 102: 2284-2299. GL
262. Thompson PD, Buchner D, Pina IL, Balady GJ, Williams MA, Marcus BH et al. American Heart Association Council on Clinical Cardiology Subcommittee on Exercise Rehabilitation Prevention; American Heart Association Council on Nutrition Physical Activity Metabolism Subcommittee on Physical Activity. Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease: a statement from the American Heart Association Council on Clinical Cardiology (Subcommittee on Nutrition, Physical Activity and Metabolism, Subcommittee on Physical Activity). Circulation. 2003; 107: 3109-3116. GL
263. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM,Walker EAet al. Diabetes Prevention Program Research Group. Reduction in the incidence of Type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002; 346: 393-403. RT
264. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P et al. Finnish Diabetes Prevention Study Group. Prevention of Type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001; 344: 1343-1350. RT
265. Orchard TJ, Temprosa M, Goldberg R, Haffner S, Ratner R, Marcovina S et al. Diabetes Prevention Program Research Group. The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. Ann Intern Med. 2005; 142: 611-619. RT
266. Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Hanrath P, Komajda M et al. Carvedilol Or Metoprolol European Trial Investigators. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet. 2003; 362: 7-13. RT
267. Giese J. Acute hypertensive vascular disease, 2: Studies on vascular reaction patterns and permeability changes by means of vital microscopy and colloidal tracer technique. Acta Pathol Microbiol Scand. 1964; 62: 497-515. OS
268. Keith NH, Wagener HP, Barker MW. Some different types of essential hypertension: their course and prognosis. Am J Med Sci. 1939; 197: 332-343. OS
269. Lip GY, Beevers M, Beevers DG. Complications and survival of 315 patients with malignant-phase hypertension. J Hypertens. 1995; 13: 915-924. OS
270. Gotto AM Jr. Review of primary and secondary prevention trials with lovastatin, pravastatin, and simvastatin.AmJ Cardiol. 2005; 96: 34F-38F.RV
271. Thavendiranathan P, Bagai A, Brookhart MA, Choudhry NK. Primary prevention of cardiovascular diseases with statin therapy: a meta-analysis of randomized controlled trials. Arch Intern Med. 2006; 166: 2307-2313. MA
272. Gorelick PB, Schneck M, Berglund LF, Feinberg W, Goldstone J. Status of lipids as a risk factor for stroke. Neuroepidemiology. 1997; 16: 107-115. RV (Pubitemid 27215859)
273. Heart Protection Study Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised plazebo-controlled trial. Lancet. 2002; 360: 7-22. RT
274. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM et al. PROSPER Study Group. PROspective Study of Pravastatin in the Elderly at Risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002; 360: 1623-1630, RT
275. Amarenco P, Bogousslavsky J, Callahan A, Goldstein LB, Hennerici M, Rudolph AE et al. Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006; 355: 549-559. RT
276. The ALLHAT Officers, Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care. The Antihypertensive and Lipid-Lowering Treatment to Prevent HeartAttack Trial (ALLHAT-LLT). JAMA. 2002; 288: 2998-3007. RT
277. Sever PS, Dahlöf B, Poulter NR,Wedel H, Beevers G, Caulfield M et al. ASCOT investigators. The prevention of coronary events and stroke with atorvastatin in hypertensive subjects with average or below average cholesterol levels. The Anglo-Scandinavian Cardiac Outcomes Trial: Lipid Lowering Arm (ASCOT:LLA). Lancet. 2003; 361: 1149-1158. RT
278. Antithrombotic Trialists Collaboration. Collaborative metaanalysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002; 324: 71-86. MA.
279. Zanchetti A, Hansson L, Dahlof B, Julius S, Menard J, Warnold I et al. Benefit and harm of low-dose aspirin in well-treated hypertensives at different baseline cardiovascular risk. J Hypertens. 2002; 20: 2301-2307. CT (Pubitemid 35388250)
280. Diener HC, Bogousslavsky J, Brass LM, Cimminiello C, Csiba L, Kaste M et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet. 2004; 364: 331-337. RT
281. Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JE et al. A randomized trial of lowdose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med. 2005; 352: 1293-1304. RT (Pubitemid 40411496)
282. Zanchetti A, Hansson L, Leonetti G, Rahn KH, Ruilope L, Warnold I et al. Low-dose aspirin does not interfere with the blood pressure lowering effects of antihypertensive therapy. J Hypertens. 2002; 20: 1015-1022. RT
283. Sanmuganathan PS, Ghahramani P, Jackson PR, Wallis EJ, Ramsay LE. Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials. Heart. 2001; 85: 265-271. MA (Pubitemid 32973555)
284. Gress TW, Nieto FJ, Shahar E, Wofford MR, Brancati FL. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. N Engl J Med. 2000; 342: 905-912. OS
285. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998; 352: 837-853. RT
286. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with Type 2 diabetes. N Engl J Med. 2003; 348: 383-393. RT (Pubitemid 36159355)
287. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ et al. Diabetes Control Complications Trial/Epidemiology of Diabetes Interventions Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with Type 1 diabetes. N Engl J Med. 2005; 353: 2643-2653. CT
288. Kearney PM, Whelton M, Reynolds K, Whelton PK, He J.Worldwide prevalence of hypertension: a systematic review. J Hypertens. 2004; 22: 11-19. RV (Pubitemid 38293521)
289. Wolf-Maier K, Cooper RS, Kramer H, Banegas JR, Giampaoli S, Joffres MR et al. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension. 2004; 43: 10-17. OS (Pubitemid 38031904)
290. Meisinger C, Heier M, Völzke H, Löwel H, Mitusch R, Hense HW et al. Regional disparities of hypertension prevalence and management within Germany. J Hypertens. 2006; 24: 293-299. OS (Pubitemid 43348240)